Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence (ARIADNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01081509
Recruitment Status : Completed
First Posted : March 5, 2010
Last Update Posted : November 16, 2011
Information provided by (Responsible Party):

Brief Summary:
The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.

Condition or disease
Breast Cancer

Study Type : Observational
Actual Enrollment : 1077 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex
Study Start Date : March 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : October 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Anastrozole

Primary Outcome Measures :
  1. Percent of patients remaining adherent to therapy with Arimidex [ Time Frame: Every 3 months ]

Secondary Outcome Measures :
  1. Questionnaire for factors influencing adherence [ Time Frame: Every 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Early breast cancer patients on adjuvant aromatase inhibitor

Inclusion Criteria:

  • Early breast cancer
  • Post menopausal
  • Adjuvant hormonal Arimidex therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01081509

Research Site
Balatonfoldvar, Hungary
Research Site
Bekescsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Dombovar, Hungary
Research Site
Gyongyos, Hungary
Research Site
Gyor, Hungary
Research Site
Gyula, Hungary
Research Site
Kaposvar, Hungary
Research Site
Kecskemet, Hungary
Research Site
Miskolc, Hungary
Research Site
Mosdos, Hungary
Research Site
Nagyatad, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Orfu, Hungary
Research Site
Papa, Hungary
Research Site
Pecs, Hungary
Research Site
Szeged, Hungary
Research Site
Szekesfehervar, Hungary
Research Site
Szekszard, Hungary
Research Site
Szentes, Hungary
Research Site
Szombathely, Hungary
Research Site
Veszprem, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Zirc, Hungary
Sponsors and Collaborators
Principal Investigator: Zsolt Horvath, M.D., Ph.D. Hungarian National Institute of Oncology

Responsible Party: AstraZeneca Identifier: NCT01081509     History of Changes
Other Study ID Numbers: NIS-OHU-ARI-2010/1
First Posted: March 5, 2010    Key Record Dates
Last Update Posted: November 16, 2011
Last Verified: November 2011

Keywords provided by AstraZeneca:
early breast cancer
Therapy adherence

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs